Does volanesorsen reduce triglyceride levels in patients with familial chylomicronemia syndrome?
Volanesorsen effectively lowers triglyceride levels in patients with familial chylomicronemia syndrome, though it is associated with thrombocytopenia and injection-site reactions.
Volanesorsen lowered triglyceride levels to less than 750 mg per deciliter in 77% of patients with familial chylomicronemia syndrome. Thrombocytopenia and injection-site reactions were common adverse events. (Funded by Ionis Pharmaceuticals and Akcea Therapeutics; APPROACH Clinical Trials.gov number, NCT02211209.).
Witztum et al. (2019) studied this question.